Cargando…

Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Palmoplantar pustulosis (PPP) causes erythematous, scaly plaques with recurrent sterile pustules refractory to treatment and with few randomized clinical trials conducted. Evidence points to involvement of interleukin 23 in the pathogenesis of PPP. OBJECTIVE: To determine the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terui, Tadashi, Kobayashi, Satomi, Okubo, Yukari, Murakami, Masamoto, Zheng, Richuan, Morishima, Hitomi, Goto, Ryosuke, Kimura, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613288/ https://www.ncbi.nlm.nih.gov/pubmed/31268476 http://dx.doi.org/10.1001/jamadermatol.2019.1394

Ejemplares similares

Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study
por: Okubo, Yukari, et al.
Publicado: (2021)

Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective
por: Yamamoto, Toshiyuki
Publicado: (2021)

Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
por: Terui, Tadashi, et al.
Publicado: (2023)

Successful Treatment of Recalcitrant Palmoplantar Pustulosis with Guselkumab
por: Jung, Jang Hwan, et al.
Publicado: (2023)

Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis
por: Yamamoto, T., et al.
Publicado: (2020)

Design and implementation of an adaptive confirmatory trial in Japanese patients with palmoplantar pustulosis
por: Zheng, Richuan, et al.
Publicado: (2022)

Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study
por: Sano, Shigetoshi, et al.
Publicado: (2018)

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Clinical characteristics and associations of palmoplantar pustulosis: an observational study()()
por: Oktem, Ayse, et al.
Publicado: (2020)

Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis
por: Benzian-Olsson, Natashia, et al.
Publicado: (2020)

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
por: Burden, A. David, et al.
Publicado: (2023)

Vesicular LL-37 Contributes to Inflammation of the Lesional Skin of Palmoplantar Pustulosis
por: Murakami, Masamoto, et al.
Publicado: (2014)

Recent advances in palmoplantar pustulosis
por: Brunasso, Alexandra Maria Giovanna, et al.
Publicado: (2021)

Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database
por: Kubota, Kiyoshi, et al.
Publicado: (2015)

Palmoplantar pustulosis and IgA nephropathy
por: Shimamura, Yoshinosuke, et al.
Publicado: (2018)

Palmoplantar Pustulosis: A Case Report
por: Dulski, Anne, et al.
Publicado: (2020)

Palmoplantar Pustulosis associated with Membranous Glomerulonephritis
por: Thakur, Vishal, et al.
Publicado: (2021)

Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
por: Terui, Hitoshi, et al.
Publicado: (2023)

A Case of Relapsing Polychondritis with Palmoplantar Pustulosis
por: Kwon, Won Joo, et al.
Publicado: (2016)

Skin-directed radiation therapy for palmoplantar pustulosis
por: King, Brian J., et al.
Publicado: (2019)

Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis
por: Spencer, Riley K., et al.
Publicado: (2023)

The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review
por: Sanchez, Isabelle M., et al.
Publicado: (2017)

Combination biologic therapy for the treatment of severe palmoplantar pustulosis
por: Torre, Kristin M., et al.
Publicado: (2017)

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments
por: Misiak-Galazka, Magdalena, et al.
Publicado: (2020)

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases
por: Marovt, Maruška, et al.
Publicado: (2021)

Relapse of Palmoplantar Pustulosis Following COVID-19 Vaccination
por: Katsuie, Shiho, et al.
Publicado: (2022)

Principal Component Analysis to Differentiate Patients with Palmoplantar Pustulosis from Those with Palmoplantar Pustular Psoriasis
por: Kim, Tae Hyung, et al.
Publicado: (2022)

Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies
por: Heidemeyer, Kristine, et al.
Publicado: (2023)

Efficacy and Safety of Oral Alitretinoin in Hand Eczema and Palmoplantar Pustulosis in Korean Patients
por: Lee, Ji Su, et al.
Publicado: (2019)

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
por: Koumaki, Dimitra, et al.
Publicado: (2019)

Improvement of palmoplantar pustulosis after excision of polyacrylamide injected into the nasal region
por: Kashiyama, Kazuya, et al.
Publicado: (2021)

SAPHO Syndrome with Palmoplantar Pustulosis as the First Manifestation Successfully Treated with Adalimumab
por: Yang, Qingyun, et al.
Publicado: (2022)

Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
por: Shibata, Tomoyuki, et al.
Publicado: (2019)

Successful treatment of adalimumab-resistant palmoplantar pustulosis with secukinumab: a case report
por: Li, Qing-Yang, et al.
Publicado: (2020)

Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study
por: Kato, Noriko, et al.
Publicado: (2021)

Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
por: Wolk, Kerstin, et al.
Publicado: (2023)

Economic Burden of Palmoplantar Pustulosis in Sweden: A Population-based Register Study
por: LÖFVENDAHL, Sofia, et al.
Publicado: (2023)

Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
por: Boisvert-Huneault, Christian, et al.
Publicado: (2023)

Amicrobial pustulosis of the folds and palmoplantar pustulosis simultaneously induced by different tumor necrosis factor-α inhibitors: Demonstration of a shared pathophysiology
por: Zirwas, Matthew, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h7aseufunup8i0nq81o3d0ping